Skip to main content
. 2023 Mar 2;14:1069411. doi: 10.3389/fneur.2023.1069411

Figure 3.

Figure 3

Plasma levels of pTau181 (A), tTau (B), NfL (C), and GFAP (D) in participants with Alzheimer's disease (AD), other neurodegenerative diseases (OND), normal cognition (CN), and mild cognitive impairment (MCI). MCI participants were stratified by the absence (stable) or presence (decline) of cognitive decline during 4 years of follow-up. Box plots show median, 25th/75th percentile, and smallest/largest value within 1.5 × the interquartile below/above the median. Select p-values are indicated in graph.